Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension.

American Journal of Hypertension
Robert D BrookKenneth A Jamerson

Abstract

The 2017 hypertension guidelines lowered systolic blood pressure (BP) goals to <130 mm Hg and redefined resistant hypertension. We investigated if these changes alter the cardiovascular benefits demonstrated by combining a calcium channel blocker (CCB), rather than hydrochlorothiazide (HCTZ), with an angiotensin-converting enzyme inhibitor (ACEI). In this post hoc analysis of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension trial (n = 11,506), we compared the primary composite outcome (cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization) between the 2 combination-treatment limbs in patients achieving a systolic BP ≤130 mm Hg and those with "apparent resistant hypertension" (prescribed ≥4 antihypertensive medications). Among study patients, 5,221 (45.4%) achieved a systolic BP ≤130 mm Hg. There were fewer primary endpoints in the amlodipine/benazepril (9.2%) vs. the HCTZ/benazepril (10.9%) limb (adjusted hazard ratio [HR] 0.83, 95% confidence interval [CI], 0.70-0.99). There were also fewer primary endpoints in the amlodipine/benazepril (12.8%) vs. the HCTZ/benazepril (...Continue Reading

References

Dec 5, 2008·The New England Journal of Medicine·Kenneth JamersonUNKNOWN ACCOMPLISH Trial Investigators
Apr 9, 2010·Journal of the American Society of Hypertension : JASH·Alan H GradmanUNKNOWN American Society of Hypertension Writing Group
Jul 2, 2010·The New England Journal of Medicine·Kenneth A JamersonMichael A Weber
Jul 14, 2010·Journal of the American College of Cardiology·Michael A WeberUNKNOWN ACCOMPLISH Investigators
Mar 19, 2011·Journal of the American Society of Hypertension : JASH·Robert D Brook, Alan B Weder
Apr 6, 2011·Circulation·Ian M KronishDevin M Mann
Sep 8, 2011·The Journal of Clinical Hypertension·Domenic A SicaLee Hamm
May 9, 2012·Hypertension·Brent M EganKristina S Yu-Isenberg
Apr 16, 2013·The American Journal of Cardiology·George BakrisUNKNOWN ACCOMPLISH Investigators
Jun 15, 2018·Drugs in Context·Carolina Guerrero-García, Alberto Francisco Rubio-Guerra
Aug 31, 2018·European Heart Journal·Bryan WilliamsUNKNOWN ESC Scientific Document Group
Oct 26, 2018·Hypertension·Robert M CareyUNKNOWN American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council
Dec 26, 2018·Hypertension·Tetsuro Tsujimoto, Hiroshi Kajio
Mar 19, 2019·The New England Journal of Medicine·Dike B OjjiUNKNOWN CREOLE Study Investigators
Mar 29, 2019·Circulation Research·Giuseppe ManciaGuido Grassi

❮ Previous
Next ❯

Citations

Feb 10, 2021·American Journal of Hypertension·Erica O Miller, John D Bisognano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.